Solventum Corp (SOLV) stock
SOLVNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3089% above fair value
$86.06−2.59 (-2.92%)
Close on Nov 17, 2026Market cap $14.65BP/E 96.7Yield –
Solventum operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Solventum's operating income for the twelve months ending Sep 30, 2026 was $454.00M, down 79.3% year over year. For fiscal 2025 it was $2.18B, up 110.5% from the year before.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.18B | +110.5% |
| FY2024 | Dec 31, 2024 | $1.04B | -38.8% |
| FY2023 | Dec 31, 2023 | $1.69B | -0.1% |
| FY2022 | Dec 31, 2022 | $1.69B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $68.00M | -96.0% |
| Q2 FY2026 | Jun 30, 2026 | $181.00M | -15.4% |
| Q1 FY2026 | Mar 31, 2026 | $81.00M | -46.7% |
| Q4 FY2025 | Dec 31, 2025 | $124.00M | -8.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.69B | +514.5% |
| Q2 FY2025 | Jun 30, 2025 | $214.00M | -12.3% |
| Q1 FY2025 | Mar 31, 2025 | $152.00M | -60.1% |
| Q4 FY2024 | Dec 31, 2024 | $136.00M | -66.5% |
| Q3 FY2024 | Sep 30, 2024 | $275.00M | -45.4% |
| Q2 FY2024 | Jun 30, 2024 | $244.00M | -41.5% |
| Q1 FY2024 | Mar 31, 2024 | $381.00M | +4.4% |
| Q4 FY2023 | Dec 31, 2023 | $406.00M | – |
| Q3 FY2023 | Sep 30, 2023 | $504.00M | – |
| Q2 FY2023 | Jun 30, 2023 | $417.00M | – |
| Q1 FY2023 | Mar 31, 2023 | $365.00M | – |
See a number that looks wrong?